Zacks Research Analysts Increase Earnings Estimates for PBH

Key Points

• Zacks Research has upgraded its Q2 2026 earnings per share estimate for Prestige Consumer Healthcare to $0.99, an increase from the previous estimate of $0.97.
• The company is currently rated as a "Strong Sell" by Zacks, with a consensus price target of $93.33 and mixed ratings from analysts—including three buy ratings and one sell rating.
• Prestige Consumer Healthcare reported a revenue of $249.53 million in its last earnings announcement, which was lower than the expected $260.71 million, reflecting a 6.6% year-over-year decline.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for shares of Prestige Consumer Healthcare in a report issued on Tuesday, September 16th. Zacks Research analyst Team now expects that the company will post earnings of $0.99 per share for the quarter, up from their previous estimate of $0.97. Zacks Research has a "Strong Sell" rating on the stock. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q2 2027 earnings at $1.19 EPS, Q4 2027 earnings at $1.27 EPS and Q1 2028 earnings at $1.27 EPS.

Several other equities analysts have also recently commented on the stock. Canaccord Genuity Group decreased their price target on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Wall Street Zen lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $93.33.

Prestige Consumer Healthcare Trading Up 0.4%

Shares of NYSE:PBH traded up $0.28 during mid-day trading on Thursday, reaching $63.38. 208,319 shares of the company were exchanged, compared to its average volume of 416,580. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. The firm has a market cap of $3.12 billion, a price-to-earnings ratio of 14.88, a P/E/G ratio of 1.99 and a beta of 0.46. The firm's 50-day simple moving average is $69.07 and its 200 day simple moving average is $78.38. Prestige Consumer Healthcare has a 1 year low of $61.93 and a 1 year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm had revenue of $249.53 million during the quarter, compared to analysts' expectations of $260.71 million. During the same period last year, the company earned $0.90 EPS. The business's quarterly revenue was down 6.6% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS.

Institutional Trading of Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC raised its position in shares of Prestige Consumer Healthcare by 35.9% in the first quarter. GAMMA Investing LLC now owns 1,879 shares of the company's stock valued at $162,000 after buying an additional 496 shares during the last quarter. KBC Group NV raised its position in shares of Prestige Consumer Healthcare by 7.4% in the first quarter. KBC Group NV now owns 2,199 shares of the company's stock valued at $189,000 after buying an additional 151 shares during the last quarter. QRG Capital Management Inc. raised its position in shares of Prestige Consumer Healthcare by 8.6% in the first quarter. QRG Capital Management Inc. now owns 5,971 shares of the company's stock valued at $513,000 after buying an additional 475 shares during the last quarter. Intech Investment Management LLC raised its position in shares of Prestige Consumer Healthcare by 18.9% in the first quarter. Intech Investment Management LLC now owns 27,307 shares of the company's stock valued at $2,348,000 after buying an additional 4,343 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in Prestige Consumer Healthcare by 14.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,315 shares of the company's stock worth $649,000 after purchasing an additional 1,030 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.